Biomonitor acquires Neutekbio

Neutekbio’s technologies and products complement perfectly Biomonitor’s current offerings to physicians and clinics involved in treatment of patients with multiple sclerosis, rheumatoid arthritis and Crohn’s disease worldwide.

Biomonitor will continue the R&D and manufacturing operations in Ireland and the ongoing collaboration with the CNRS, a French research organization in cell biology, virology, and medicine in Paris.

Arsalan Kharazmi, CEO of Biomonitor, said: With the acquisition of Neutekbio we have become the leading theranostic company, which offers a very broad range of assays for patient monitoring as well as supporting pharma/biotech industry in their biopharmaceutical drug development programs.

Dr. Robert Erickson, former CEO of Neutekbio and currently managing director of the Galway-based operation, has said that this was a strategically important event for the company. He said: “Neutekbio has established product development laboratories, ISO13485 certified manufacturing facilities and have recently introduced three products to the marketplace. I am confident that synergies inherent in this acquisition will be realized in a timely manner.”

Sunstone Capital in Denmark has rendered financial support to the acquisition.

Soren Lemonius, chairman of Biomonitor and partner in Sunstone Capital, said: We are committed to supporting Biomonitor in becoming a leader in monitoring and improving costly protein based therapies – also by acquisition of supplementary products and technologies when possible.